Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

NCT01516983 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Brain Metastases

Interventions

DRUG: icotinib
RADIATION: Whole brain radiotherapy

Sponsor

Betta Pharmaceuticals Co., Ltd.